Preview Mode Links will not work in preview mode

Some stories require a little more – a little more discussion, more context, more depth and breadth. 

That’s the idea behind “Behind the Blue” – a weekly podcast created by UK Strategic Communications. It is designed to explore through probing interviews the in-depth the stories that make UK the university for Kentucky and that have impact across the institution, the Commonwealth and, in some cases, the world. 

"Behind the Blue" is available on iTunes, Google Play, Stitcher and Spotify. Become a subscriber to receive new episodes of “Behind the Blue” each week. UK’s latest medical breakthroughs, research, artists and writers will be featured, along with the most important news impacting the university.

For questions or comments about this or any other episode of "Behind the Blue," email BehindTheBlue@uky.edu or tweet your question with #BehindTheBlue. Transcripts for this or other episodes of Behind the Blue can be downloaded from the show’s blog page.

To discover what’s wildly possible at the University of Kentucky, click here.

Jan 21, 2020

LEXINGTON, Ky. (Jan. 21, 2020) – The University of Kentucky recently received $3 million from the National Institute on Drug Abuse and National Institute on General Medical Sciences to fund new opioid-related research in the criminal justice system.

Known as the Geographic variation in Addiction Treatment (GATE) study, the 5-year project is led by Carrie Oser, professor of sociology in the UK College of Arts & Sciences. Oser and her colleagues will be focusing on the factors that influence a person’s decision to use one of the three FDA-approved medications for the treatment of opioid use disorder (OUD) – methadone, buprenorphine and extended-release naltrexone.

Although research shows that these medications are highly effective at reducing opioid use, infectious disease transmission, and drug-related criminal behavior, uptake of these medications is low – only about 7% of people with OUD receive medications – and more than half of KY counties do not have any providers who prescribe medications for OUD.  It is even more challenging for those involved in the criminal justice system. In the past few years, the Kentucky Department of Corrections has addressed this issue by making naltrexone available inside their institutions and is currently piloting expansion at three prisons by offering buprenorphine to individuals with OUD that meet clinical and medical protocols.

On this episode of Behind the Blue, Oser talks with UKPR’s Allison Perry about the GATE study and its goals, to identify how a person’s individual characteristics, personal networks and structural factors influence their decision whether or not to take medication for OUD both during incarceration and following release, and it will specifically look at the differences between urban and rural populations. While other studies have looked at individual and structural factors as predictors of medication use, this study is unique in its focus on the people surrounding the person with OUD and how their support – or lack thereof – and opinions influences decisions on taking medication.

"Behind the Blue" is available on iTunes, Google Play, Stitcher and Spotify. Become a subscriber to receive new episodes of “Behind the Blue” each week. UK’s latest medical breakthroughs, research, artists and writers will be featured, along with the most important news impacting the university.

For questions or comments about this or any other episode of "Behind the Blue," email BehindTheBlue@uky.edu or tweet your question with #BehindTheBlue.

To discover what’s wildly possible at the University of Kentucky, click here.